The 2025 ASSET-IT trial investigated whether early intravenous infusion of tirofiban, an antiplatelet agent, following intravenous thrombolysis could improve outcomes in patients with acute noncardioembolic ischemic stroke who are not eligible for thrombectomy. This phase 3, double-blind, randomized, placebo-controlled study … Read More
tirofiban
RESCUE BT2 Trial: Tirofiban for Acute Ischemic Stroke
Summary of the RESCUE BT2 Trial: Tirofiban in Acute Ischemic Stroke Background: Methods: Inclusion criteria: Results: Conclusions: Key Takeaways: Source